Independent study shows Pillcheck improves treatment for depression and anxiety

Ruslan Dorfman, PhD, MBA14 Jun 2024

A randomized controlled trial showed that people suffering from depression and anxiety recovered faster when their medications were optimized using Pillcheck pharmacogenetics testing (also known as pharmacogenomics or PGx testing). The study evaluated the impact of pharmacogenomics-guided prescribing versus standard antidepressant treatment of depression and anxiety in three large community pharmacies. Pillcheck technology supported community pharmacists in providing evidence-based PGx-guided recommendations for patient therapy. Depression, generalized anxiety and disability improved faster for participants who received PGx-guided treatment than those who received standard treatment.

Results were published on February 28, 2021. Click the image below to read the full journal article.

Pharmacogenomics guided versus standard antidepressant treatment in a community pharmacy setting: A randomized controlled trial https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.12986

 

Back to blog

About the author

Ruslan Dorfman

Ruslan Dorfman

PhD, MBA

Founder and CSO Ruslan Dorfman is a trailblazer in personalized medicine, a molecular geneticist, and technology builder. Inspired by direct interactions with Cystic Fibrosis families from all over the world, Dr. Dorfman co-founded GeneYouIn to facilitate access to advanced genetics for the general public. He managed large-scale R&D programs at Sick Kids Hospital, Toronto. He advised Bridgepoint and Mount Sinai hospitals on the implementation of personalized medicine programs. Dr. Dorfman has published thirty peer-reviewed papers on the genetics of Cystic Fibrosis and Pain.